Kathleen Dungan, MD, MPH
Division of Endocrinology, Diabetes & Metabolism
Ohio State University Wexner Medical Center
Charles P. Vega, MD, FAAFP
Clinical Professor, Family Medicine
Director, UC Irvine Program in Medical Education for the Latino Community
Associate Dean, School of Medicine
University of California, Irvine
Cardiovascular disease (CVD) is the leading cause of death among patients with type 2 diabetes (T2D). Among the potential cardiovascular complications of T2DM, stroke is a particularly high risk for patients, especially given the aging population. Increasing rates of diabetes, hypertension, and obesity are also placing a larger population of younger patients at risk for stroke. Some antidiabetic therapies, including certain glucagon-like peptide-1 (GLP-1) receptor agonists, can reduce the CVD risks in patients with T2D and contribute to secondary prevention. Expert faculty discussions in this Phone-a-Friend series will address specific challenges related to the management of patients with T2D, the risk of stroke, and the roles of GLP-1 receptor agonists.
The educational design of this activity addresses the needs of endocrinologists, neurologists, cardiologists, and primary care providers (PCPs), including nurse practitioners (NPs) and physician assistants (PAs), who manage patients with type 2 diabetes (T2D) at risk for stroke.
After completing this activity, participants will be better prepared to:
Discuss recent clinical trial data, including cardiovascular outcomes trials, guidelines, and prescribing recommendations for GLP-1 receptor agonists for T2D
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour(s) (which includes 0.1 hour(s) of pharmacology).
Disclosure of Conflicts of Interest
Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the ACCME and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Kathleen Dungan, MD - Consulting Fee: DexCom, Inc., Eli Lilly and Company, Novo Nordisk Inc.; Contracted Research: Abbott, DexCom, Inc., Novo Nordisk Inc., Sanofi S.A., ViaCyte, Inc.
Charles P. Vega, MD - Consulting fees: GlaxoSmithKline plc., Johnson & Johnson
The planners and managers have the following relevant financial relationships with ineligible companies:
Kristin Delisi, NP: Nothing to disclose
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Lauren Sinclair: Nothing to disclose
Gena Dolson, MS: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions to Receive Credit
In order to receive credit, participants must complete the following:
- Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
- Complete the Preactivity Questions.
- Review the activity content.
- Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Global Education Group Contact Information
For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or firstname.lastname@example.org.